Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt Publisher Pubmed

Passweg JR¹ ; Labopin M² ; Cornelissen J³ ; Volin L⁴ ; Socie G⁵ ; Huynh A⁶ ; Tabrizi R⁷ ; Wu D⁸ ; Craddock C⁹ ; Schaap N¹⁰ ; Kuball J¹¹ ; Chevallier P¹² ; Cahn JY¹³ ; Blaise D¹⁴ Show All Authors

Passweg JR¹
Labopin M²
Cornelissen J³
Volin L⁴
Socie G⁵
Huynh A⁶
Tabrizi R⁷
Wu D⁸
Craddock C⁹
Schaap N¹⁰
Kuball J¹¹
Chevallier P¹²
Cahn JY¹³
Blaise D¹⁴
Ghavamzadeh A¹⁵
Bilger K¹⁶
Ciceri F¹⁷
Schmid C¹⁸
Giebel S¹⁹
Nagler A²⁰
Mohty M²¹

Source: Bone Marrow Transplantation Published:2015

Abstract

In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics. © 2015 Macmillan Publishers Limited.

Related Docs

View other Related Docs

1. Trends in Patient Outcome Over the Past Two Decades Following Allogeneic Stem Cell Transplantation for Acute Myeloid Leukaemia: An Alwp/Ebmt Analysis, Journal of Internal Medicine (2019)

2. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis, Transplantation and Cellular Therapy (2025)

3. Outcomes of Haploidentical Peripheral Stem Cell Transplantation With Combination of Post-Transplant Cyclophosphamide (Ptcy) and Anti-Thymocyte Globulin (Atg) Compared to Unrelated Donor Transplantation in Acute Myeloid Leukemia: A Retrospective 10-Year Experience, Leukemia Research (2022)

Experts (# of related papers)

View all Related Experts

Seyed Asadollah Mousavi (8)

Mohammad Vaezi (7)

Other Related Docs

4. Survival of Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation: An Experience in Developing Country, International Journal of Hematology-Oncology and Stem Cell Research (2022)

5. Outcomes of Hematopoietic Stem Cell Transplantation From Unmanipulated Haploidentical Versus Matched Sibling Donor in Patients With Acute Myeloid Leukemia in First Complete Remission With Intermediate or High-Risk Cytogenetics: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Haematologica (2018)

6. Abo Mismatch Is Associated With Increased Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation (2015)

7. Refined Graft-Versus-Host Disease/Relapse-Free Survival in Transplant From Hla-Identical Related or Unrelated Donors in Acute Myeloid Leukemia, Bone Marrow Transplantation (2018)

8. What Is the Outcome in Patients With Acute Leukaemia Who Survive Severe Acute Graft-Versus-Host Disease?, Journal of Internal Medicine (2018)

9. Prognostic Value of Runx1 Mutations in Aml: A Meta-Analysis, Asian Pacific Journal of Cancer Prevention (2018)

10. Sickle Cell Disease: An International Survey of Results of Hla-Identical Sibling Hematopoietic Stem Cell Transplantation, Blood (2017)

11. Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare Between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation, International Journal of Hematology-Oncology and Stem Cell Research (2021)

12. Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study, Bone Marrow Transplantation (2020)

13. Prognostic Factors for Survival After Allogeneic Transplantation in Acute Myeloid Leukemia in Iran Using Censored Quantile Regression Model, Scientific Reports (2025)

14. A Single Center Study of Prescribing and Treatment Outcomes of Patients With Chronic Myeloid Leukemia, International Journal of Hematology-Oncology and Stem Cell Research (2020)

15. Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia, Clinical Lymphoma# Myeloma and Leukemia (2020)

16. Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study, Health Science Reports (2025)

17. Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-Term Follow-Up, Cell Transplantation (2023)

18. Impact of Anti-Thymocyte Globulin on Results of Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Philadelphia-Positive Acute Lymphoblastic Leukaemia: An Analysis by the Acute Leukemia Working Party of the Ebmt, European Journal of Cancer (2019)

19. Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of Non-M3 Acute Myeloid Leukemia, Iranian Journal of Blood and Cancer (2016)

20. Age-Related Considerations in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: A 10-Year Retrospective Study, International Journal of Hematology-Oncology and Stem Cell Research (2025)

Style	Citing Format
MLA	Passweg JR, et al.. "Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt." Bone Marrow Transplantation, vol. 50, no. 8, 2015, pp. 1063-1068.
APA	Passweg JR, Labopin M, Cornelissen J, Volin L, Socie G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, ... Mohty M (2015). Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt. Bone Marrow Transplantation, 50(8), 1063-1068.
Chicago	Passweg JR, Labopin M, Cornelissen J, Volin L, Socie G, Huynh A, Tabrizi R, et al.. "Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt." Bone Marrow Transplantation 50, no. 8 (2015): 1063-1068.
Harvard	Passweg JR et al. (2015) 'Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt', Bone Marrow Transplantation, 50(8), pp. 1063-1068.
Vancouver	Passweg JR, Labopin M, Cornelissen J, Volin L, Socie G, Huynh A, et al.. Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt. Bone Marrow Transplantation. 2015;50(8):1063-1068.
BibTex	@article{ author = {Passweg JR and Labopin M and Cornelissen J and Volin L and Socie G and Huynh A and Tabrizi R and Wu D and Craddock C and Schaap N and Kuball J and Chevallier P and Cahn JY and Blaise D and Ghavamzadeh A and Bilger K and Ciceri F and Schmid C and Giebel S and Nagler A and Mohty M}, title = {Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt}, journal = {Bone Marrow Transplantation}, volume = {50}, number = {8}, pages = {1063-1068}, year = {2015} }
RIS	TY - JOUR AU - Passweg JR AU - Labopin M AU - Cornelissen J AU - Volin L AU - Socie G AU - Huynh A AU - Tabrizi R AU - Wu D AU - Craddock C AU - Schaap N AU - Kuball J AU - Chevallier P AU - Cahn JY AU - Blaise D AU - Ghavamzadeh A AU - Bilger K AU - Ciceri F AU - Schmid C AU - Giebel S AU - Nagler A AU - Mohty M TI - Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt JO - Bone Marrow Transplantation VL - 50 IS - 8 SP - 1063 EP - 1068 PY - 2015 ER -